Full Press Release Details
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10 th Annual Healthcare Conference to be held in New York City, on October 20 th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.
| Presentation Details | |
| Date / time: | October 20, 2026, 9:15 AM ET |
| Format: | Fireside chat |
| Location: | Holmes II, Lotte New York Palace |
| Webcast Link | Here |
The webcast may also be accessed through Spero's website on the Events + Presentations page. A replay will be available for approximately 90 days following the conference. To request a meeting or for more details about the conference please contact your institutional representative at Chardan.
About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company's lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.